IND submission for ONCR-021 still planned for mid-2023, subject to receipt of additional funding Ended the...
false000167181800016718182023-05-122023-05-12 UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549 ...
UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549 SEC FILE NUMBER: 001-39575 CUSIP NUMBER: 68236R103 FORM...
false000167181800016718182023-05-022023-05-02 UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549 ...
YestrueNoYes--12-310001671818NoFY00016718182022-01-012022-12-3100016718182023-03-2000016718182022-06-30xbrli:sharesiso4217:USD ...
false000167181800016718182023-04-292023-04-29 UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549 ...
--12-310001671818three yearsfalseFY0001671818us-gaap:LeaseholdImprovementsMember2022-12-310001671818srt:Maximu...
0001671818false00016718182023-03-242023-03-24 UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549 ...
Reprioritized product portfolio to focus on IV-administered, self-amplifying RNA medicinesOn track to submit...
false000167181800016718182023-03-142023-03-14 UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549 ...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A UNDER...
Research collaboration leverages Oncorusβ proprietary ionizable amines, PEG lipids, LNP formulations, process...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.